1 Recommendations

1 Recommendations

1.1 Evidence on the safety of transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids raises no major safety concerns. However, evidence on its efficacy is limited in quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

1.2 Clinicians wishing to do transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids should:

  • Inform the clinical governance leads in their healthcare organisation.

  • Give patients clear written information to support shared decision making, including NICE's information for the public.

  • Ensure that patients (and their families and carers as appropriate) understand the procedure's safety and efficacy, and any uncertainties about these.

  • Audit and review clinical outcomes of all patients having the procedure. The main efficacy and safety outcomes identified in this guidance can be entered into NICE's interventional procedure outcomes audit tool (for use at local discretion).

  • Discuss the outcomes of the procedure during their annual appraisal to reflect, learn and improve.

1.3 Healthcare organisations should:

  • Ensure systems are in place that support clinicians to collect and report data on outcomes and safety for every patient having this procedure.

  • Regularly review data on outcomes and safety for this procedure.

1.4 During the consent process clinicians should tell patients that the procedure may not fully relieve their symptoms and further procedures may be needed.

1.5 Further research should include comparative studies, preferably randomised controlled trials. It should report details of patient selection, disease-specific quality of life and long-term outcomes.

  • National Institute for Health and Care Excellence (NICE)